Compare Spotify Technology (SPOT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs Vertex Pharmaceuticals Incorporated — how do they compare? Spotify Technology trades at $493.4 (market cap $101.23B), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| SPOT | VRTX | |
|---|---|---|
Market Cap | $101.23B | $121.95B |
Sector | Media | Health |
52-Week High | $738.53 | $529.59 |
52-Week Low | $412.75 | $366.54 |
Enterprise Value | $91.81B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $493.23, up 3.16% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with support at $481 and resistance at $500. Fundamentally, revenue grew to $17.19B in 2025 with net income surging to $2.21B, reflecting improved profitability. Recent developments include AI feature expansions and parent-managed accounts for free users, enhancing growth prospects.
Outlook remains positive with analyst consensus target at $617, though rich valuation (P/E 33.54) and competition pose risks. Earnings growth and AI integration present opportunities, but investors should monitor execution against high expectations and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
